@article{dfb1200df0194b6c9c561156d91134ff,
title = "Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan",
abstract = "Objective: The aim of this study was to investigate the application of sacubitril/valsartan in clinical practice and the utility of PREDICT-HF score for outcome prediction in Asian heart failure patients with difference risk profiles. Methods: The TAROT-HF study was a multicenter, single-arm, observational study. Totally 1,187 outpatients with HFrEF treated with sacubitril/valsartan were enrolled and categorized by: (1) high-risk group with ≥1 of the following three risk factors: old age (≥80 years), low baseline systolic blood pressure (<100 mmHg), and renal impairment (eGFR <30 ml/min/1.73 m2), and (2) standard-risk group, those who did not have any risk factors. Clinical outcomes were assessed using the PREDICT-HF risk model. Results: A total of 305 (25.7%) patients matched the criteria for the high-risk group. The event rates of cardiovascular death or first unplanned heart failure hospitalization (HFH) among the overall population, high-risk, and standard-risk groups were 13.7, 24.9, and 10.8 events per 100 patient-years, respectively. The C statistics for the PREDICT-HF model in the overall cohort and high-risk group for cardiovascular death or first unplanned HFH at 2 years were 0.73 (95% CI 0.70–0.76) and 0.71 (95% CI 0.65–0.76), respectively. The permanent discontinuation rate among the high-risk patients was significantly higher than that among the standard-risk patients (8.3 vs. 2.5 per 100 patient-years, p < 0.001). Conclusions: Real-world outcomes of the TAROT-HF study demonstrated that the PREDICT-HF model performed well in Asian HFrEF patients. Three easily detected clinical profiles of age, renal function, and systolic BP could help to identify patients at risk before initiating sacubitril/valsartan.",
keywords = "heart failure, high-risk population, PREDICT-HF model, sacubitril/valsartan, TAROT-HF",
author = "Hsu, {Chien Yi} and Chang, {Hung Yu} and Chao, {Chieh Ju} and Chiou, {Wei Ru} and Lin, {Po Lin} and Chung, {Fa Po} and Lin, {Wen Yu} and Huang, {Jin Long} and Liang, {Huai Wen} and Liao, {Chia Te} and Lee, {Ying Hsiang}",
note = "Funding Information: The present work was supported by the following research grants: Taiwan Society of Cardiology (TSOC 107-0505), Cheng Hsin General Hospital (CHGH111-(N)09; CHGH111-(N)10), Taipei Medical University and Taipei Medical University Hospital (109TMU-TMUH-16, 110TMU-TMUH-14, 111TMUH-MOST-21), and the Ministry of Science and Technology (MOST-110-2314-B-038-131). The funding institutions took no part in the study design, data collection or analysis, publication intent, or manuscript preparation. Publisher Copyright: Copyright {\textcopyright} 2022 Hsu, Chang, Chao, Chiou, Lin, Chung, Lin, Huang, Liang, Liao and Lee.",
year = "2022",
month = jul,
day = "25",
doi = "10.3389/fcvm.2022.950389",
language = "English",
volume = "9",
journal = "Frontiers in Cardiovascular Medicine",
issn = "2297-055X",
publisher = "Frontiers Media S. A.",
}